Stay updated on Pembrolizumab & Epacadostat in Thymic Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Epacadostat in Thymic Carcinoma Clinical Trial page.

Latest updates to the Pembrolizumab & Epacadostat in Thymic Carcinoma Clinical Trial page
- Check3 days agoChange DetectedThe page's revision was updated from v3.6.4 to v3.6.5, indicating a minor platform update. There is no indication that study content, eligibility criteria, or results text has changed.SummaryDifference0.1%

- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedPage revision updated from v3.6.3 to v3.6.4, representing a minor update to the page metadata. This change does not affect the study details, endpoints, or eligibility criteria.SummaryDifference0.1%

- Check25 days agoNo Change Detected
- Check39 days agoChange DetectedThe page now shows a newer revision line (v3.6.3) for the study documents, replacing the previous v3.6.2. This reflects an updated protocol/SAP version in the documents section.SummaryDifference0.1%

- Check46 days agoChange DetectedThe page shows an updated revision tag, replacing v3.6.0 with v3.6.2, reflecting a newer deployment of the page system. This change does not modify study content or related data.SummaryDifference0.1%

- Check61 days agoChange DetectedNew user-help sections were added, and the page revision and verification status indicators were updated to reflect current study details.SummaryDifference2%

- Check68 days agoChange DetectedPage revision updated from v3.5.4 to v3.5.5, signaling a minor update to the ClinicalTrials.gov record's content/metadata.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab & Epacadostat in Thymic Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Epacadostat in Thymic Carcinoma Clinical Trial page.